DEF: Celcuity Inc. Seeks Stockholder Approval for 3 Million Share Increase to Incentive Plan at 2025 Annual Meeting

Celcuity Inc. is holding its 2025 Annual Meeting of Stockholders on May 13, 2025, to vote on key proposals including the election of directors, ratification of the accounting firm, executive compensation, and a significant increase to the stock incentive plan.

Summary

• Celcuity Inc. will hold its 2025 Annual Meeting of Stockholders on May 13, 2025, at its Minneapolis offices.
• Stockholders will vote on the election of seven director nominees, ratification of Boulay PLLP as the independent accounting firm, approval of executive compensation, and a 3,000,000 share increase to the 2017 Stock Incentive Plan.
• The record date for voting eligibility is March 17, 2025.
• As of March 17, 2025, there were 37,839,392 shares of common stock outstanding.
• The Board recommends voting FOR all proposals.
• The company is seeking approval for a 3,000,000 share increase to the Amended and Restated 2017 Stock Incentive Plan to attract and retain employees.
• The company's 2024 Annual Report on Form 10-K is available for review.
• The company's non-employee directors receive an annual equity award with a fair market value of $80,000 and a cash retainer of $30,000.
• The company has adopted a clawback policy that allows for recovery of excess incentive-based compensation in the event of a required restatement of our financial statements, which is intended to comply with Nasdaq Rule 5608.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the agenda for the annual meeting and seeking approval for routine matters. The sentiment is neutral to slightly positive, reflecting the company's efforts to maintain good corporate governance and attract/retain talent.

Positives

• The proposed increase in the stock incentive plan aims to attract and retain talent, which is crucial for a growing biopharmaceutical company.
• The Board is actively engaged in corporate governance, with committees overseeing audit, compensation, and nominations.
• The company has adopted a clawback policy that allows for recovery of excess incentive-based compensation in the event of a required restatement of our financial statements, which is intended to comply with Nasdaq Rule 5608.

Negatives

• The company has a history of net losses, as indicated in the Pay Versus Performance section.
• The company's stock price decreased by approximately 1% from December 31, 2021 to December 31, 2024.

Risks

• Failure to secure stockholder approval for the proposed increase to the stock incentive plan could hinder the company's ability to attract and retain key personnel.
• The company's reliance on equity-based compensation may be affected by fluctuations in the stock price.
• The company's future success depends on the successful development and commercialization of its targeted therapies.

Future Outlook

The company anticipates the need to maintain competitive compensation levels for existing employees and to add new employees as it continues to execute its clinical development and commercialization plans.

Industry Context

In the biopharmaceutical industry, equity grants are a significant component of compensation packages offered to employees.

Comparison to Industry Standards

• The document mentions that the Compensation Committee approved changes to bring the design and total target direct compensation of the Company's named executive officers into closer alignment with similarly situated companies.
• However, no specific companies or benchmarks are provided for a detailed comparison.

Corporate Governance

Related Party Transactions

• Brian F. Sullivan, the Chairman of the Board and our Chief Executive Officer, participated in the private placement and purchased 260,869 shares of common stock for an aggregate purchase price of $1,499,996.75 and was issued warrants to purchase 104,340 shares of common stock, on the same terms and conditions as the other Investors under the Securities Purchase Agreement.

Stakeholder Impact

• Approval of the stock incentive plan increase could positively impact employees by providing them with equity-based compensation.
• The advisory vote on executive compensation allows stockholders to express their views on the company's pay practices.
• The election of directors determines the leadership and oversight of the company.

Next Steps

• Stockholders are encouraged to vote on the proposals before the Annual Meeting on May 13, 2025.
• The Board will consider the results of the advisory vote on executive compensation when making future decisions.

Key Dates

Keywords

stockholders, incentive plan, directors, compensation, Celcuity, proxy